Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

22 June 2026 : Original article  

[In Press] Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant Recipients

Agnieszka Kuczaj ORCID logo1ABCDEFG, Szymon Warwas ORCID logo1BCDEF, Mikołaj Tyrka ORCID logo1BDEF, Błażej Skotnicki ORCID logo1BDEF, Daniel Szymecki1BDEF, Oliwia Jewuła ORCID logo1BDEF, Joanna Śliwka ORCID logo1ADEF, Szymon Pawlak ORCID logo1ADEF, Piotr Przybyłowski ORCID logo1ADEF, Tomasz Hrapkowicz ORCID logo1ADEF

DOI: 10.12659/AOT.952888

Ann Transplant In Press; DOI: 10.12659/AOT.952888  

Available online: 2026-06-22, In Press, Corrected Proof

Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule

Abstract

BACKGROUND
COVID-19 significantly impacted the outcomes of patients, particularly those with comorbidities, including solid organ transplant recipients. The aim of this study was to investigate the incidence and mortality of COVID-19, as well as to identify independent risk factors associated with COVID-19–related death in patients undergoing orthotopic heart transplantation (OHT).
MATERIAL AND METHODS
The study followed 556 heart transplant recipients at a high-volume transplant center in Poland from March 2020 to March 2024. Patients were classified as infected based on a positive result from reverse transcription-polymerase chain reaction (RT-PCR) tests or SARS-CoV-2 antigen rapid tests performed on nasopharyngeal swab samples.
RESULTS
In the analyzed cohort, 189 of 556 patients (33.99%; 40 women, 21.16%) were diagnosed with COVID-19 following OHT. In total, 15 patients (7.94%) experienced recurrent SARS-CoV-2 infections, with 1 patient being diagnosed 3 times. A total of 33 patients (5.94%) required hospitalization due to COVID-19. Among the entire study cohort, 75 patients (13.49%) died, with 18 of these deaths (24%) directly attributable to COVID-19. In the multivariable analysis, vaccination against COVID-19 was identified as a protective factor against death due to the virus (OR, 0.22; 95% CI, 0.07-0.68; P=0.009) while increasing age was associated with a higher risk of mortality (OR, 1.08; 95% CI, 1.02-1.14; P=0.008).
CONCLUSIONS
The lack of COVID-19 vaccination and advanced age significantly influenced the COVID-19–related mortality risk.

Keywords: COVID-19; Heart Transplantation; Immunosuppression Therapy; Mortality; SARS-CoV-2

In Press

Original article  

iTRAQ- and MRM-Based Proteomics Identify Early Injury Biomarkers for Primary Dysfunction After Liver Transp...

Ann Transplant In Press; DOI: 10.12659/AOT.952366  

Case report  

Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case Series

Ann Transplant In Press; DOI: 10.12659/AOT.951715  

Original article  

Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.952251  

Original article  

The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...

Ann Transplant In Press; DOI: 10.12659/AOT.952031  

Most Viewed Current Articles

24 Aug 2021 : Review article   20,504

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article   16,603

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

05 Apr 2022 : Original article   15,871

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   15,778

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358